Company Filing History:
1 out of 9 
1 out of 14 Years Active: 2022
Title: Thomas Kindler: Innovator in FLT3 Inhibitors
Introduction
Thomas Kindler is a notable inventor based in Mainz, Germany. He has made significant contributions to the field of pharmacology, particularly in the development of FLT3 inhibitors. His work focuses on creating small molecule compounds that can be used in the treatment of various diseases, including acute myeloid leukemia (AML).
Latest Patents
Thomas Kindler holds a patent for the "Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) inhibitors." This invention relates to small molecule compounds of formula (I) and their application as FLT3 inhibitors for treating diseases such as AML. The patent also details methods for synthesizing these compounds and outlines treatment methodologies.
Career Highlights
Throughout his career, Thomas has worked with prestigious institutions, including the University of Regensburg and Universitätsmedizin der Johannes Gutenberg-Universität Mainz. His research has been pivotal in advancing the understanding and treatment of hematological malignancies.
Collaborations
Thomas has collaborated with notable colleagues, including Siavosh Mahboobi and Andreas Sellmer. These partnerships have contributed to the successful development of his innovative compounds.
Conclusion
Thomas Kindler's work in the field of FLT3 inhibitors represents a significant advancement in cancer treatment. His innovative approach and dedication to research continue to impact the medical community positively.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.